These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 7692125)
1. [Cardiomyopathy in the course of treating Hodgkin's disease in a 12-year old girl]. Wójtowicz J; Hryniewicz A; Rosłan K Kardiol Pol; 1993 Jul; 39(7):27-30. PubMed ID: 7692125 [TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). Lipton JH; Gospodarowicz M; Reingold S Hematol Oncol; 1996 Mar; 14(1):29-31. PubMed ID: 8613133 [TBL] [Abstract][Full Text] [Related]
3. [Cardiogenic shock during polychemotherapy in a patient with Hodgkin's disease]. Drzewoski J; Chojnowski K; Olszańska-Skorek T; Krykowski E Kardiol Pol; 1986; 29(8):555-9. PubMed ID: 2435945 [No Abstract] [Full Text] [Related]
4. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages? Andrieu JM; Colonna P J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234 [No Abstract] [Full Text] [Related]
5. Acute promyelocytic leukemia following ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy for Hodgkin's disease. Amadori S; Papa G; Anselmo AP; Fidani P; Mandelli F; Biagini C Cancer Treat Rep; 1983 Jun; 67(6):603-4. PubMed ID: 6190561 [No Abstract] [Full Text] [Related]
6. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Brosteanu O; Hasenclever D; Loeffler M; Diehl V; Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867 [TBL] [Abstract][Full Text] [Related]
7. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Castelo-Branco C; Nomdedeu B; Camus A; Mercadal S; Martínez de Osaba MJ; Balasch J Fertil Steril; 2007 Mar; 87(3):702-5. PubMed ID: 17173900 [TBL] [Abstract][Full Text] [Related]
8. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute. Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748 [TBL] [Abstract][Full Text] [Related]
9. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood. van Beek RD; Smit M; van den Heuvel-Eibrink MM; de Jong FH; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Weber RF; Pieters R; de Muinck Keizer-Schrama SM Hum Reprod; 2007 Dec; 22(12):3215-22. PubMed ID: 17981817 [TBL] [Abstract][Full Text] [Related]
10. Pohl-Pinkus constrictions of hair following chemotherapy for Hodgkin's disease. Williamson PJ; de Berker D Br J Haematol; 2005 Mar; 128(5):582. PubMed ID: 15725077 [No Abstract] [Full Text] [Related]
11. Hodgkin's disease and the risk of acute leukemia in successfully treated patients. Valagussa P; Bonadonna G Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571 [No Abstract] [Full Text] [Related]
12. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease. Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235 [TBL] [Abstract][Full Text] [Related]
13. [Treating Hodgkin's disease: for whom the more means better?]. Illés A Magy Onkol; 2004; 48(2):157-61. PubMed ID: 15351812 [TBL] [Abstract][Full Text] [Related]
14. [Cured from Hodgkin's disease]. Brice P Bull Cancer; 2002; 89(7-8):666-70. PubMed ID: 12206979 [TBL] [Abstract][Full Text] [Related]
15. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center]. Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222 [TBL] [Abstract][Full Text] [Related]
16. [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma]. Zhen ZJ; Sun XF; Xia Y; Wang ZH; Ling JY Ai Zheng; 2006 Apr; 25(4):471-5. PubMed ID: 16613683 [TBL] [Abstract][Full Text] [Related]
17. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
18. [Hodgkin's disease in pregnancy--case report and literature review]. Schäffer M; Hegenbart U; Klostermann K; Stepan H Z Geburtshilfe Neonatol; 2003; 207(2):71-3. PubMed ID: 12740750 [TBL] [Abstract][Full Text] [Related]
19. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: possible synergy. Matthews JH Lancet; 1993 Oct; 342(8877):988. PubMed ID: 7692199 [No Abstract] [Full Text] [Related]
20. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V; J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]